Novel pharmacotherapies for heart failure

Indranee N. Rajapreyar, Andrew J. Lenneman, Sumanth D. Prabhu

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


In this chapter, we summarize the pharmacological treatment of heart failure (HF), a heterogeneous clinical syndrome with complex pathophysiology that, in most cases, ultimately results from left ventricular (LV) remodeling and systolic and/or diastolic dysfunction of the heart. The primary focus of the review is recently approved and emerging pharmacotherapies; guideline directed medical therapy (GDMT) is also briefly discussed. The pharmacologic management of heart failure can be challenging due its underlying heterogeneity and variability in disease trajectory. Currently, neurohormonal blocking agents are the mainstay of GDMT in HF with reduced ejection fraction (HFrEF, LVEF <40%). However, human studies of neurohormonal inhibition have not consistently demonstrated benefit in HF with preserved EF (HFpEF). Moreover, despite therapeutic advances, the mortality rates for both HFrEF and HFpEF remain unacceptably high, indicating that new treatment approaches are needed. Several emerging therapies with novel mechanisms of action are currently under investigation in preclinical and clinical trials and will be discussed in this section.

Original languageEnglish
Title of host publicationEmerging Technologies for Heart Diseases
Subtitle of host publicationVolume 1: Treatments for Heart Failure and Valvular Disorders
Number of pages22
ISBN (Electronic)9780128137062
StatePublished - Jan 1 2020


  • Heart failure with preserved ejection fraction
  • Heart failure with reduced ejection fraction
  • Pathophysiology
  • Pharmacotherapy


Dive into the research topics of 'Novel pharmacotherapies for heart failure'. Together they form a unique fingerprint.

Cite this